Biora Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BIOR Nasdaq 8731 https://www.bioratherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biora Therapeutics Inc

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology - Apr 8th, 2024 12:00 pm
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development - Apr 4th, 2024 12:00 pm
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Apr 3rd, 2024 8:05 pm
Biora Therapeutics Full Year 2023 Earnings: Beats Expectations - Apr 1st, 2024 7:39 pm
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Apr 1st, 2024 12:00 pm
BIOR: Negotiations Accelerating - Mar 27th, 2024 4:35 pm
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript - Mar 27th, 2024 4:18 pm
Q4 2023 Biora Therapeutics Inc Earnings Call - Mar 27th, 2024 10:18 am
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results - Mar 26th, 2024 8:05 pm
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update - Mar 18th, 2024 12:00 pm
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset - Mar 11th, 2024 12:00 pm
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600 - Feb 26th, 2024 1:00 pm
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium - Feb 8th, 2024 1:00 pm
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co. - Jan 22nd, 2024 1:00 pm
Biora Therapeutics Provides Outlook for 2024 - Jan 16th, 2024 1:00 pm
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600 - Jan 8th, 2024 1:00 pm
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform - Jan 2nd, 2024 1:00 pm
BIOR: Capitalizing on Progress: BT-600 to Start - Dec 20th, 2023 10:21 am
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform - Dec 19th, 2023 1:00 pm
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors - Dec 18th, 2023 1:00 pm